Heart disease & heart failure
IV mesenchymal stem cell protocols for ischemic and non-ischemic cardiomyopathy. Strict candidacy: stable patients on optimized cardiology care, with realistic expectations about adjunctive benefit.
- Class
- Cardiovascular
- Approach
- IV systemic
- Materials
- MSC · MPC · exosome
- Coordination
- With cardiology
01 About
Heart failure, briefly.
Heart failure is the impaired ability of the heart to pump blood — most commonly resulting from prior myocardial infarction (ischemic cardiomyopathy) or from progressive non-ischemic causes (dilated, hypertensive, or other cardiomyopathies). Standard treatment is medical optimization (ACE/ARB/ARNI, beta-blockers, MRA, SGLT2 inhibitors), device therapy when indicated, and lifestyle modification.
Stem cell therapy is being studied as an addition to optimized medical management — not as a replacement. The goal is to support myocardial tissue, modulate post-MI inflammation, and potentially improve left ventricular function in patients who remain symptomatic on standard care.
02 How it works
How regen supports the heart.
Mesenchymal stem cells delivered systemically modulate cardiac inflammation, support angiogenesis through paracrine signaling (VEGF release), and may reduce fibrosis around infarct zones. Exosome material delivers similar signaling without live cells. Cardiac MSC therapy is one of the larger evidence bases in regenerative medicine — accumulated over 20+ years of trials.
This is not a replacement for guideline-directed medical therapy. Patients should remain on their cardiologist's recommended regimen. Regen sits as a possible adjunct for those who remain symptomatic or whose function continues to decline despite optimized treatment.
03 What the research shows
What the studies show.
Cardiac stem cell therapy has one of the longest and largest evidence bases in regenerative medicine — accumulated over decades. Recent meta-analyses suggest meaningful effects on mortality and left ventricular function, though debate continues about the cell type, dose, and delivery route that drive the most benefit.
MSC Transplantation for Major Adverse Cardiovascular Events and Cardiac Function in Chronic Heart Failure
A 2024 meta-analysis pooled 17 randomized controlled trials (1,684 patients) of MSC transplantation for chronic heart failure. The pooled analysis suggests reductions in all-cause mortality, improvements in left ventricular ejection fraction, and reductions in scar size — supporting the hypothesis that MSCs can deliver meaningful adjunctive benefit in optimized HF patients.
Read on PubMed CentralTargeted Transendocardial Mesenchymal Precursor Cell Therapy in Heart Failure
The DREAM-HF trial — a randomized, sham-controlled study of transendocardial mesenchymal precursor cell (MPC) injection in patients with chronic HFrEF — showed reduced major adverse cardiac events in pre-specified subgroups with elevated inflammatory markers. The trial helped clarify which HF patient subgroup benefits most.
Read on JACCCardiopoietic Stem Cell Therapy in Heart Failure (C-CURE)
A foundational trial in cardiac regenerative medicine. C-CURE was a multicenter randomized trial in patients with ischemic heart failure. Cardiopoietic-conditioned MSCs delivered by endomyocardial injection significantly improved LVEF compared to standard care alone, without increased toxicity.
Read on PubMed
Cardiac stem cell therapy is one of the more mature regenerative indications by trial volume — but candidate selection still matters. We are explicit about who is and isn't a fit, and we work in close coordination with the patient's cardiologist.
04 Are you a candidate
Who's a candidate.
Candidates:
- Stable ischemic or non-ischemic cardiomyopathy on optimized guideline-directed therapy.
- NYHA class II–III heart failure with persistent symptoms despite medical management.
- Patients with reduced ejection fraction (HFrEF) seeking adjunct supportive therapy.
- Stable medical status with active cardiology follow-up.
When we will not recommend it:
- Acute decompensated heart failure or unstable angina.
- Patients not on optimized guideline-directed medical therapy — fix that first.
- End-stage disease where transplant or LVAD is the appropriate path.
- Patients seeking to reduce or stop their cardiac medications.
Think you might be a candidate?
The first step is a 60–90 minute consultation. We review your imaging, history, and goals — and tell you honestly whether regenerative therapy is the right next step.
05 A patient experience
Dr. Abdullah is the doctor you'll want to have. Patient, calm, listens attentively. I'll wholeheartedly recommend this place to my family and loved ones.
Mickhail Bobga Google · 5.0
07What happens at your consultation
A conversation, not a sales meeting.
-
01
Intake & history
60–90 minutes. We review imaging, prior treatments, current medications, and goals. Most of this hour is listening.
-
02
Focused exam
A clinical exam tailored to your indication. Range of motion, strength, functional testing — what the literature actually predicts response on.
-
03
Honest candidacy review
If we think you're a candidate, we'll tell you why. If we don't, we'll tell you what we'd recommend instead — surgery, PT, watchful waiting.
-
04
Written plan & pricing
A defined treatment plan with modality, sequence, follow-up cadence, and total cost — before any commitment.
06 What treatment looks like
What treatment looks like.
A cardiac protocol at Apex begins with cardiology coordination, full medical workup, recent echocardiography, and review of medications. Treatment is IV systemic MSC and/or exosome material in a series of doses. We do not perform transendocardial or intramyocardial delivery — those remain in clinical-trial settings at specialized centers.
Reassessment at 3, 6, and 12 months. Repeat echocardiography, cardiac biomarker tracking, functional capacity (6-minute walk), and ongoing cardiology coordination.
09 Common questions
Common questions, answered.
Will this replace my cardiac medications?
No. We coordinate with your cardiologist — guideline-directed medications stay.
Is this safe with my reduced ejection fraction?
Yes for stable HFrEF on optimized therapy. Acute decompensation is a contraindication.
Has this been tried in patients like me?
Yes — over 1,600 patients across 17 randomized trials. The evidence base is one of the largest in regenerative medicine.
Can it improve my ejection fraction?
Pooled data suggests yes — modest but reproducible LVEF improvement alongside reduced major adverse events in select subgroups.
Do I need to be referred by my cardiologist?
Not required — but we coordinate directly with your cardiologist before any protocol.
What are the risks?
IV MSC protocols are well-tolerated in cardiac trials. Brief post-infusion fatigue is the most common minor effect.
08 Coverage & cost
Most regenerative protocols at Apex are not covered by insurance — we discuss pricing directly, in writing, before any commitment. Softwave shockwave is the exception: covered by Medicare Parts A & B with supplement (not by Medicare Advantage). Financing options are available for protocols not covered. We never hold a pricing conversation until we know you're a candidate.
Begin with a consultation.
A frank conversation about your heart disease, your current cardiology care, and whether IV MSC therapy is the right adjunct — and what the evidence actually supports for your specific clinical picture.